Doctolib's 40% Secondary Market Devaluation: Primary Drivers of European HealthTech Market Recalibration

Nelson Advisors
Apr 5
11 min read

Structural Devaluation and Strategic Reorientation: A Comprehensive Analysis of Doctolib’s Market Recalibration from 2022 to 2026

The valuation trajectory of Doctolib between the first half of 2022 and the first quarter of 2026 represents a seminal case study in the maturation of the European HealthTech ecosystem. During this period, the company’s implied market value shifted from a primary funding peak of €5.8 Billion to a secondary transaction valuation of €3.6 Billion, marking a 40% decrease that has sparked extensive debate among industry analysts and institutional investors.

Source: https://www.bloomberg.com/news/articles/2026-04-02/startup-doctolib-s-valuation-slides-38-in-secondary-share-sale

This adjustment occurs despite the company’s sustained operational growth, characterised by an annual recurring revenue (ARR) reaching €422 Million by the end of 2025. The divergence between rising fundamental performance and declining equity valuation is not an isolated phenomenon but is symptomatic of a broader "tech market normalisation" that has recalibrated the premiums once afforded to high-growth, venture-backed enterprises.

The primary catalyst for the current €3.6 Billion valuation was a €300 Million secondary share sale facilitated by long-term employees and early angel investors seeking liquidity after more than a decade of company operations]. This transaction, involving prominent new backers such as the Strüngmann family office ATHOS KG, Denmark’s A.P. Moller Holding, and Generation Investment Management (GenIM), highlights a strategic shift from speculative capital to "industrial-grade" institutional support.

To understand this 40% devaluation, one must analyse the confluence of macroeconomic multiple compression, the technical mechanics of secondary market discounts, the post-pandemic stabilisation of telemedicine demand, and the pivot toward enterprise-wide profitability in a high-interest-rate environment.

The Macroeconomic Paradigm Shift: From Speculative Fervor to Rational Exuberance

The valuation of €5.8 Billion established in March 2022 was the product of a unique historical moment characterised by near-zero interest rates and an unprecedented acceleration of digital transformation in healthcare.

By 2026, the cost of capital had fundamentally altered the discounted cash flow (DCF) models used by growth equity firms. The tech-heavy Nasdaq index’s 7% decline in early 2026 is merely the most recent indicator of a sustained trend where investors have aggressive discounted future cash flows in favor of present-day profitability.

The Collapse of the Growth-at-All-Costs Multiple

In late 2021 and early 2022, top-tier SaaS and HealthTech companies were trading at revenue multiples that exceeded 18x to 20x. Doctolib’s €5.8 Billion valuation on an estimated revenue base of €250 Million to €300 Million placed it firmly within this elite, albeit speculative, bracket, with an implied price-to-sales multiple of approximately 19.3x to 23x.

By March 2026, the median public SaaS revenue multiple had compressed to 3.4x, reflecting a broader market realisation that the era of hyper-expansion subsidised by cheap venture capital had ended.

Period	Valuation	ARR (Est.)	Implied Multiple (Multiple=ARREV)
Q1 2022	€5.8 Billion [User Query]	~€270 Million	~21.5x
Q1 2026	€3.6 Billion [User Query]	~€422 Million [User Query]	~8.5x

As the table illustrates, while Doctolib’s revenue grew by over 50%, its multiple compressed by more than 60%. This compression is the primary driver of the 40% valuation drop. In a high-interest-rate environment, the value of a dollar earned ten years from now is significantly lower than it was in 2021.

For a company like Doctolib, which was not yet profitable at the time of its Series G raise, this shift in the discount rate exerted immediate downward pressure on its "paper" valuation.

The Technical Nature of Secondary Transaction Discounts

A critical nuance in the €3.6 billion figure is that it stems from a secondary share sale rather than a primary financing round. In the private markets of 2026, secondary transactions are fundamentally different from primary rounds in their pricing mechanisms. Primary rounds involve the issuance of new equity to fund growth, whereas secondary rounds involve existing shareholders selling their stakes to new investors.

Secondary shares typically trade at a "liquidity discount" of 10% to 30% relative to the last primary round.

This discount compensates the buyer for several risks:

Illiquidity: The shares cannot be sold on a public exchange and have no definitive exit timeline.
Preference Gap: Secondary shares are often common stock or lack the liquidation preferences and anti-dilution protections granted to primary investors in later rounds.
Information Asymmetry: Secondary buyers may have less access to internal company data than lead investors in a primary round.

The €3.6 Billion valuation thus represents a "fair market value" for a block of shares being sold for cash today, rather than a theoretical enterprise value for the whole company in a competitive bidding process.

For Doctolib’s management, accepting a lower valuation for this "small secondary round" was now doubt a strategic choice to satisfy the liquidity needs of angel investors and long-term employees who had been with the company since its 2013 founding.

Post-Pandemic Normalisation and the Telemedicine Plateau

Doctolib’s earlier, higher valuation was significantly buoyed by the "COVID-19 effect". During the pandemic, the company became an essential infrastructure provider, particularly in France, where it handled the logistics of national vaccine rollouts. This period saw a massive spike in telemedicine adoption, with virtual consultations jumping from 1% of total medical visits to 17% in a matter of months.

The Reversion to Hybrid Care Models

By 2026, the "telemedicine-only" hype of 2021 had settled into a more nuanced "hybrid care" reality. Market data from 2022 through 2026 shows that telemedicine usage has stabilised at approximately 4% to 6% of all consultations. While this is a permanent and significant increase from pre-pandemic levels, it fell short of the 20% to 30% penetration rates that some investors had projected during the peak of the crisis.

Metric	Pre-Pandemic (2019)	Pandemic Peak (2020/21)	Normalization (2022-26)
Telemed % of Visits	~1%	17%	4% - 6%
Doctolib Focus	Booking Utility	Emergency Health Infrastructure	Healthcare Operating System

This normalisation forced a recalibration of Doctolib’s growth trajectory. The company transitioned from a phase of "forced adoption" to one where it had to prove the long-term efficiency gains of its platform in a post-crisis environment.The market no longer values Doctolib as a pandemic beneficiary but as a standard utility, which naturally commands a more conservative multiple.

From "Booking App" to "Healthcare Operating System": Strategic Reorientation

To counter multiple compression and declining pandemic tailwinds, Doctolib has undergone a fundamental product transformation. In 2022, the platform was largely viewed as a digital gateway for patient appointments. By 2026, the company is positioning itself as an integrated "Operating System" for healthcare professionals, harmonising administrative, clinical and financial workflows.

The Integration of Agentic and Ambient AI

Doctolib’s R&D strategy, which saw an investment of €115 Million in 2024 alone, is centred on the integration of artificial intelligence into the clinician’s daily workflow. Doctolib launched an "Ambient AI Scribe," a tool that converts spoken patient-doctor dialogue into structured clinical documentation. This technological shift is designed to address the global shortfall of 11 Million healthcare workers by reducing the administrative documentation time by an estimated 50%.

The business implication of this shift is profound. By moving from a "booking fee" model to a "clinical efficiency" model, Doctolib can justify higher subscription tiers. Currently, practitioners pay a baseline of €139 per month, but the full suite of integrated services, including AI scribing, automated reception via Aaron.ai and financial management tools—can cost up to €500 per month.

Operational Efficiency and the Path to Profitability

In the era of "Rational Exuberance," the most critical metric for a late-stage startup is the "Rule of 40," defined by the formula:

$Score = Revenue Growth Rate + EBITDA Margin

A score above 40% is considered the gold standard for SaaS health. Doctolib has spent the 2023-2025 period aggressively moving toward this benchmark by narrowing its losses.

Year	Revenue (ARR)	Adjusted EBITDA	Net Loss Reduction
2023	€284.1M	-€87.1M	-
2024	€348.0M	-€53.8M	38%
2025	€422.0M [User Query]	Breakeven	~100% (Projected)

The reduction in losses from €87.1 Million to €53.8 Million in a single year demonstrates a disciplined management team capable of balancing high R&D intensity (33% of revenue) with fiscal responsibility. This transition is a prerequisite for the company’s anticipated IPO in late 2026 or 2027, as public market investors in the current regime are unwilling to subsidise "unprofitable growth".

Competitive Landscape and European Market Maturity

Doctolib’s 2026 position is also defined by its relative dominance in the European market compared to peers like Poland’s DocPlanner. While DocPlanner has raised significantly less capital ($141 Million compared to Doctolib’s ~$866 Million), it remains a formidable rival in fragmented markets like Italy and Spain.

Consolidation and Regional Dynamics

The European digital health market has moved from a period of "fragmented speculation" to one of "strategic consolidation". Doctolib has successfully defended its home market of France, where it supports 19 Million patients and 200,000 healthcare professionals, while aggressively expanding into Germany. Germany now accounts for approximately 20% of Doctolib’s total ARR and is the primary driver of new growth, contributing 28% of new revenues in Q1 2025

However, international expansion is a double-edged sword for valuation. While it increases the addressable market, the "slow and tricky" nature of recruiting doctors in different regulatory environments (as noted by DocPlanner’s CFO) means that customer acquisition costs (CAC) remain high. This slower-than-expected international uptake compared to the lightning-fast growth in France has likely contributed to the more conservative 2026 valuation.

Company	Total Funding	Employees	Patient Base	Market Strategy
Doctolib	~$866M	~3,500	~80M (EU)	Integrated OS
DocPlanner	~$141M	~1,500	~30M (Global)	Market Aggregator

Comparison with US Peers: Hinge Health and Omada

When benchmarked against US peers like Hinge Health, Doctolib’s valuation compression appears part of a global reset. Hinge Health, valued at $6.2 Billion in 2021, filed for an IPO in 2025 with a target valuation of only $2.6 Billion, reflecting a similar 50%+ reduction in enterprise value despite growing revenues.

Doctolib’s 40% drop is actually "resilient" compared to some US peers, likely due to its more stable, subscription-based European revenue model, which is less sensitive to the employment cycles that impact US employer-driven health plans.

Regulatory Darwinism: The EU AI Act and Compliance Moats

A subtle but powerful factor in Doctolib’s 2026 valuation is the "Compliance Moat" created by the European regulatory environment. As of March 2026, the full enforcement of the EU AI Act has created a binary filter for investors.

The Valuation Premium for Regulatory Compliance

Companies that have achieved Medical Device Regulation (MDR) certification and comply with the "high-risk" AI standards of the EU AI Act now command a 20-30% valuation premium. This is because compliant assets represent a "turnkey" solution for strategic buyers (like Siemens or Roche) who want to enter the digital health market without facing an 18-to-24-month regulatory bottleneck.

Analysing the New Investor Pool: ATHOS, GenIM, and A.P. Moller

The €300 Million secondary sale brought in a new class of investors whose presence provides deep insight into the company’s future. The shift from traditional Venture Capital (like Accel or Eurazeo) to family offices and industrial holdings (ATHOS KG, A.P. Moller Holding) suggests a transition from "exit-seeking" capital to "value-building" capital.

Rationale of New Institutional Backers

ATHOS KG: The family office of the Strüngmann brothers, who famously backed BioNTech. Their investment signals a belief in Doctolib’s long-term role as a central pillar of the European medical infrastructure.
A.P. Moller Holding: Known for long-term "industrial" investments. Their participation suggests that Doctolib is no longer viewed as a high-risk tech startup but as a foundational utility platform with predictable, subscription-based cash flows.
Generation Investment Management (GenIM): Chaired by Al Gore, GenIM focuses on sustainable, long-term growth. Their involvement underscores Doctolib’s "B-Corp" status and its social utility in solving the healthcare worker shortage.

These investors are comfortable with a "flat" or "discounted" valuation in 2026 because they are pricing the asset based on its 2030 potential rather than its 2021 hype. Their entry at €3.6 Billion effectively sets a "floor" for the valuation and de-risks the eventual path to an IPO.

The IPO Horizon (2026-2027): Valuation Recovery and Listing Dilemmas

As the company enters the 2026-2027 IPO window, the focus shifts to whether it can reclaim its €5.8 Billion (or $6.4 Billion) peak. Current analysts suggest an IPO target in the range of $6 billion to $8 Billion, contingent on several factors.

Factors for a Successful Public Debut

Demonstrated Profitability: The company must prove it can be EBITDA-positive while maintaining a 20%+ growth rate.
The "Delaware Flip": There is strategic debate about whether Doctolib should list on a US exchange (NASDAQ) to capture higher valuation multiples or remain on Euronext as a European champion. A US listing might offer 20-30% higher multiples but would require a complex legal restructuring.
Market Sentiment: The success of "bellwether" listings, such as Belgium’s Agomab Therapeutics, has indicated that investor appetite for "de-risked European assets" is returning in early 2026.

Valuation Benchmarks for 2026 IPOs

Metric	Digital Health Platform Target	Doctolib 2026 Position
Gross Margin	60% - 80%	~65% - 70%
ARR per FTE	$150k - $200k	~$130k (Estimating ~3,500 staff)
NRR (Net Retention)	>110%	High (99% subscription based)
Regulatory Status	Compliant (AI Act/MDR)	High Moat

Doctolib’s position as a "category leader in waiting" is strong, but the valuation gap between €3.6 Billion and the €6-8 Billion target must be filled by proof of AI-driven margin expansion.

Conclusion: Synthesising the 40% Devaluation

The 40% decrease in Doctolib’s valuation from Q1 2022 to Q1 2026 is a multifaceted phenomenon that reflects the maturation of both the company and the broader tech market. It was caused not by a decline in business utility, as evidenced by the growth to €422 Million ARR, but by a dramatic shift in how the market prices that utility..

The primary drivers of this recalibration include:

The Correction of "Pandemic Premium": The realisation that telemedicine is a hybrid supplement rather than a wholesale replacement for in-person care.
Interest Rate Reality: The end of the "Growth at All Costs" era, which forced a transition from 20x multiples to 8x multiples.
Secondary Market Mechanics: The technical requirement of providing liquidity to early backers at a market-clearing discount.
Strategic Reinvestment: The decision to prioritise a €115 Million R&D budget (33% of revenue) to build a defensible AI-driven "Operating System" rather than chasing immediate short-term profitability during a market downturn.

Far from being a sign of distress, the €3.6 Billion valuation and the accompanying €300 Million secondary sale represent a "cleaning" of the cap table. By replacing early, risk-averse angels with industrial giants like A.P. Moller and ATHOS, Doctolib has secured the patient capital necessary to navigate the final steps toward an IPO.

The company is no longer a "startup" in the speculative sense; it is a mature European health infrastructure provider entering a new era of "Industrial Maturity". The success of its AI initiatives and its expansion in Germany will ultimately determine if the next phase of its financial journey, the public markets, will see a return to the premiums of its pandemic-era peak.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech